N/A
Completed N=4
Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease · Pulmonary Emphysema
Source: ClinicalTrials.gov NCT01110252 ↗
Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcomePrimary: Forced Vital Capacity (FVC) — 1.5; 2.1 liters
Summary
The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Forced Vital Capacity (FVC) |
1.5; 2.1 | — |
| PRIMARY Forced Expiratory Volume (FEV1) |
0.7; 0.8 | — |
| PRIMARY Vital Capacity - VC |
1.8; 1.4 | — |
| SECONDARY Arterial Blood Gases Test - Pa O2 |
69; 57 | — |
| SECONDARY Arterial Blood Gases Test - Pa CO2 |
48.75; 89.25 | — |
Eligibility Criteria
Inclusion Criteria
- diagnosis of severe chronic obstructive pulmonary disease
- ineffective clinical treatment
- limited life expectancy
- limitations in daily physical activity
- possibility of pulmonary rehabilitation physiotherapy
- acceptable nutritional status
- acceptable cardiac function
- at least six months smoking cessation
- family support
- modified medical research council dyspnea scale stage > 3
Exclusion Criteria
- pulmonary or extra-pulmonary infection
- severe coronary disease and/or ventricular dysfunction
- significant kidney or liver disease
- immunosuppressive disease
- active smoker
- cancer
- psychosocial problems
- established medical protocol
- family rejection
- pregnancy
Data sourced from ClinicalTrials.gov (NCT01110252). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.